October 2007 | Nefrología

A collection of structuralized and critical summaries of the nephrology literature

C. Quereda, F. García López, V. Barrio

Nefrologia (English Version). 2007;27 Supl 5:1-3

Full text access

Share

Is tacrolimus effective as monotherapy in primary membranous glomerulonephritis?

M. Cobo, D. Hernández

Nefrologia (English Version). 2007;27 Supl 5:4-5

Full text access

Share

What are the effectiveness and safety of low-dose Cyclosporin as monotherapy or combined with corticosteroids used as induction and long-term therapy in idiopathic membranous nephropathy with nephrotic syndrome?

X. Fulladosa

Nefrologia (English Version). 2007;27 Supl 5:6-7

Full text access

Share

Is Azathioprine maintenance therapy equivalent to Cyclosporin A therapy to prevent recurrences of proliferative forms of lupus nephritis?

A. Segarra, C. Quereda

Nefrologia (English Version). 2007;27 Supl 5:8-9

Full text access

Share

Can Azathioprine and corticosteroids maintenance therapy replace Cyclophosphamide and corticosteroids in proliferative lupus nephritis in terms of efficacy and safety?

C. Quereda , F. García López

Nefrologia (English Version). 2007;27 Supl 5:10-1

Full text access

Share

Does the implementation of an educational and health care professionals alert system including patient education on essential AHT improve the management of this disease?

A. M. Tato, F. García López

Nefrologia (English Version). 2007;27 Supl 5:12-3

Full text access

Share

Is it better to use an ACE inhibitor (lysinopril) rather than a calcium-channel blocker (amlodipine) for managing hypertension patients with high cardiovascular risk?

R. Marín Iranzo

Nefrologia (English Version). 2007;27 Supl 5:14-5

Full text access

Share

Can blood pressure control independently reduce the risk for developing microalbuminuria in type 2 Diabetes patients without diabetic nephropathy?

A. Martínez-Castelao, J. L. Górriz, C. Quereda

Nefrologia (English Version). 2007;27 Supl 5:16-7

Full text access

Share

Does the target of an Hb value of 13.5 g/dL versus 11.3 g/dL in EPO-managed stages 3 and 4 chronic renal disease decrease cardiovascular events and mortality?

R. Saracho

Nefrologia (English Version). 2007;27 Supl 5:18-9

Full text access

Share

Is it better to normalize hemoglobin rather than partially correcting anemia in stages 3-4 chronic renal disease patients to decrease cardiovascular events?

R. Saracho Rotaeche

Nefrologia (English Version). 2007;27 Supl 5:20-1

Full text access

Share

How do the different hemoglobin therapeutic targets affect the mortality and cardiovascular events when managing anemia with different erythropoiesis-stimulating agents in chronic renal failure?

F. García López

Nefrologia (English Version). 2007;27 Supl 5:22-3

Full text access

Share

Does therapy with spironolactone increase the effect of ACEIs and ARA-II for managing proteinuria and renal failure progression in patients with chronic renal disease?

A. Ramos, C. Caramelo

Nefrologia (English Version). 2007;27 Supl 5:24-5

Full text access

Share

What are the benefits and risks of calcimimetic agents in the management of secondary hyperparathyroidism in chronic renal failure?

F. Rivera

Nefrologia (English Version). 2007;27 Supl 5:26-7

Full text access

Share

What is the role of progenitor endothelial cells in chronic renal disease?

A. Ramos, C. Caramelo

Nefrologia (English Version). 2007;27 Supl 5:28-9

Full text access

Share

Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia?

F. Ortiz

Nefrologia (English Version). 2007;27 Supl 5:30-1

Full text access

Share

Is the incidence of acute renal failure (ARF) lower by using selective nonsteroidal anti-inflammatory drugs (NSAIDs)?

V. Barrio Lucía, F. García López

Nefrologia (English Version). 2007;27 Supl 5:32-3

Full text access

Share

Besides N-acetylcysteine, which among other regimens better prevents iodinated radiocontrast media-associated nephropathy: hydration with normal saline, with sodium bicarbonate, or both with ascorbic acid (vitamin C)?

V. Barrio, M. Velo

Nefrologia (English Version). 2007;27 Supl 5:34-5

Full text access

Share

Does furosemide administration improve the prognosis or the need for replacement therapy in acute renal failure?

V. Barrio, C. Quereda

Nefrologia (English Version). 2007;27 Supl 5:36-7

Full text access

Share

Does adding dialysis doses to continuous hemofiltration improve the prognosis in acute renal failure (ARF)?

V. Barrio, F. Liaño

Nefrologia (English Version). 2007;27 Supl 5:38-9

Full text access

Share

Do vesicoureteral reflux and/or antibiotic prophylaxis have an influence on the recurrence of pyelonephritis, urinary infections, and occurrence of renal scars after the first episode of acute pyelonephritis?

M. Espino Hernández

Nefrologia (English Version). 2007;27 Supl 5:40-1

Full text access

Share

Can intensification of the nocturnal session of automated peritoneal dialysis be compared with, or even improve, the outcomes from prescription based on diurnal supplementary changes, while improving the patients'' quality of life?

M. Pérez Fontán, A. Rodríguez Carmona

Nefrologia (English Version). 2007;27 Supl 5:42-3

Full text access

Share

Is high peritoneal transport an independent risk factor for mortality and/or survival in peritoneal dialysis patients?

M. J. Fernández-Reyes, M. A. Bajo

Nefrologia (English Version). 2007;27 Supl 5:44-5

Full text access

Share

Does the pigtail catheter offer better outcomes than straight swan-neck Tenckhoff catheter?

G. del Peso, M. A. Bajo

Nefrologia (English Version). 2007;27 Supl 5:46-7

Full text access

Share

As compared with standard solutions, do low-content glucose degradation products (GDPs) peritoneal dialysis solutions improve the patient''s survival?

C. Remón, P. L. Quirós

Nefrologia (English Version). 2007;27 Supl 5:48-9

Full text access

Share

Are ANDY-Disc® and Ultrabag® connection systems comparable in terms of peritonitis rate and technique survival in peritoneal dialysis patients?

P. L. Quirós, C. Remón

Nefrologia (English Version). 2007;27 Supl 5:50-1

Full text access

Share

EIs the follow-up of quality indicators and combined achievement of several goals associated with better clinical outcomes in hemodialysis patients?

F. Álvarez-Ude, M. D. Arenas

Nefrologia (English Version). 2007;27 Supl 5:52-3

Full text access

Share

Does immunosuppressive induction with anti-thymocyte globulin offer any advantage over anti-IL-2R monoclonal antibodies in patients with deaddonor renal transplant and high risk for delayed graft function or acute rejection?

J. J. Amenábar Iríbar, F. J. García López

Nefrologia (English Version). 2007;27 Supl 5:54-5

Full text access

Share

Does the use of ACEI/ARA-II have any influence on patients and graft survival after renal transplantation?

D. Hernández, M. Cobo

Nefrologia (English Version). 2007;27 Supl 5:56-7

Full text access

Share

Does a therapeutic regimen without anti-calcineurin agents entail a low risk for acute rejection in pediatric renal transplant?

J. M. Díaz

Nefrologia (English Version). 2007;27 Supl 5:58-9

Full text access

Share

Hemoglobin target levels in chronic renal failure: evidence and clinical practice guidelines

F. García López, R. Saracho

Nefrologia (English Version). 2007;27 Supl 5:60-4

Full text access

Share

Instructions for doing a structuralized summary and critical analysis of an observational study

D. Hernández

Nefrologia (English Version). 2007;27 Supl 5:65-7

Full text access

Share

Subscribe to our newsletter